Scholarlink

<p> Cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitor (ICI) therapy can disrupt the course of oncology treatment. Data guiding the safety and effectiveness of biologics for cirAEs remain limited. We therefore aimed to evaluate the efficacy and oncologic safety of biologic therapy for ICI-associated cirAEs. We conducted a retrospective review of adult patients at Beth Israel Deaconess Medical Center from January 1st 2015 to July 31st 2025 who received biologic therapy from a dermatologist for a cirAE in the setting of immunotherapy for a malignancy. We collected demographics, cirAE phenotype, biologic used, cirAE outcomes, ICI treatment course, and cancer status before and after biologic initiation. We included twenty-two patients with 30 discrete cirAEs. The most common cirAE phenotypes were psoriasiform (36%), immunobullous (29%), and eczematous (26%) eruptions. Overall, 19/22 patients (86%) achieved complete resolution of their cirAE on biologic therapy. Among patients whose ICIs were held or discontinued, 6/18 (33%) successfully resumed immunotherapy after cutaneous improvement on biologic therapy. No patient experienced a change in cancer status from before to after biologic treatment. Our findings suggest that biologics are highly effective for treating a range of ICI-induced cirAE and appear safe in this population, with no adverse impact on cancer status. Biologic therapy may allow for salvage of ICI treatment in a subset of patients, potentially improving overall cancer outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biologic treatment for cutaneous immune-related adverse events in cancer patients undergoing immune-checkpoint therapy: a retrospective review

  • 期刊论文

  • 发表日期：

    2026年5月2日

查看全文
  • Juna Khang,
  • Elif Karatas,
  • Rebeca Martinez,
  • Jean S. McGee,
  • Katherine Brag

摘要

Cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitor (ICI) therapy can disrupt the course of oncology treatment. Data guiding the safety and effectiveness of biologics for cirAEs remain limited. We therefore aimed to evaluate the efficacy and oncologic safety of biologic therapy for ICI-associated cirAEs. We conducted a retrospective review of adult patients at Beth Israel Deaconess Medical Center from January 1st 2015 to July 31st 2025 who received biologic therapy from a dermatologist for a cirAE in the setting of immunotherapy for a malignancy. We collected demographics, cirAE phenotype, biologic used, cirAE outcomes, ICI treatment course, and cancer status before and after biologic initiation. We included twenty-two patients with 30 discrete cirAEs. The most common cirAE phenotypes were psoriasiform (36%), immunobullous (29%), and eczematous (26%) eruptions. Overall, 19/22 patients (86%) achieved complete resolution of their cirAE on biologic therapy. Among patients whose ICIs were held or discontinued, 6/18 (33%) successfully resumed immunotherapy after cutaneous improvement on biologic therapy. No patient experienced a change in cancer status from before to after biologic treatment. Our findings suggest that biologics are highly effective for treating a range of ICI-induced cirAE and appear safe in this population, with no adverse impact on cancer status. Biologic therapy may allow for salvage of ICI treatment in a subset of patients, potentially improving overall cancer outcomes.